

Population Insights Report

Characteristics of the Patient Population with Metabolic and Endocrine Conditions Receiving Health Care Services Across Clinical Research Networks Participating in PCORnet®

Rationale for Network Query of PCORnet Data Resources:

This report characterizes the population of patients with metabolic and endocrine conditions and recorded ambulatory encounters at a health care setting across PCORnet® between January 1 – December 31, 2024.

The report aligns with the Patient-Centered Outcomes Research Institute's® (PCORI®) strategic goal to demonstrate ways PCORnet can be used to address national-scale patient-centered comparative clinical effectiveness research (CER) questions. The results in this report may support planning for future patient-centered CER using PCORnet.

Background on PCORnet:

PCORnet is a large, distributed “network of networks” funded by PCORI to improve the nation’s capacity to efficiently conduct health research, particularly patient-centered comparative clinical effectiveness research (CER).

The unique federated architecture of the network enables network sites to query clinical encounter data to identify patients and contact them for recruitment in research studies (with the appropriate regulatory and legal agreements). PCORnet has been used to conduct more than 300 studies, including pragmatic trials, observational research, and data science studies. PCORnet® Population Insights Reports are created to provide descriptive insights into the feasibility of research questions and the potential to recruit patients for future research using PCORnet.

At the time of this report, PCORnet® Network Partners include Clinical Research Networks (CRNs) with more than 70 data-contributing sites in addition to Patient Partners and the Coordinating Center for PCORnet®. As the recent 2025 PCORnet Population Insights report details, collectively, these data-contributing sites are connected to nearly 47 million people in the U.S. Clinical sites include large academic health systems, hospitals, federally qualified health centers, and community clinics.

For more information on the structure and governance of PCORnet, please see the [PCORnet® Playbook](#).

Population Report Description:

This report describes the results of a data query of the patients with selected metabolic and endocrine conditions that had at least 1 face-to-face ambulatory encounter and a recorded diagnosis code (e.g., ICD-10) at a health care setting across PCORnet between January 1 – December 31, 2024. The query used a 5-year “look-back” period to identify patients with diagnosis codes for specific metabolic and endocrine conditions that were reflected in the electronic medical record. The query results will enhance public

awareness of the population of patients with metabolic and endocrine conditions as well as diagnosis codes related to overweight and obesity across sites participating in PCORnet that potentially would be available for future health care research.

Data Query Methodology and Criteria:

The Coordinating Center and network subject matter experts collaborated with PCORI to develop the specifications and criteria for this data query. While there are myriad conditions which may fall under the umbrella of metabolic and endocrine conditions, collaborators identified a set of common conditions to be considered for this query. Investigators pursuing a funding opportunity who are interested in characterizing additional metabolic and endocrine conditions across PCORnet that are not specified in this report should contact the PCORnet® Front Door.

The query identified demographic and geographic characteristics of the general patient population with at least 1 ambulatory encounter at a site participating in PCORnet during the 1-year query period (January 1, 2024 – December 31, 2024). From this reference population, the query characterized patients who had a diagnosis code for given metabolic or endocrine conditions in their electronic medical record within a 5-year period (January 1, 2020 – December 31, 2024). The data query also described co-occurring metabolic and endocrine conditions, additional co-occurring conditions, and stratified the reference population by specific medications related to metabolic and endocrine disorders.

Additional methods and information used to specify the query and define the cohorts are available upon request by emailing frontdoor@pcornet.org.

The Coordinating Center programmed and distributed this data query to 71 of the data contributing partners in PCORnet.

Population Report Results

71 PCORnet data-contributing partners contributed data to this report, reflecting the experience of patients who received health care services across sites participating in PCORnet during a 1-year period (January 1 – December 31, 2024).

Results of the query are provided in tables referenced below:

- **Tables 1-2.** Demographic characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024
- **Table 3.** Demographic characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to overweight or obesity between January 1, 2020 – December 31, 2024.
- **Table 4-5.** Geographic and care setting characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.
- **Table 6.** Geographic and care setting characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to overweight or obesity metabolic or endocrine conditions between

January 1, 2020 – December 31, 2024.

- **Table 7.** Medications prescribed related to metabolic and endocrine conditions for patients with at least 1 ambulatory visit at a site participating in PCORnet between January 1, 2024 – December 31, 2024.
- **Tables 8-9.** Overlap between metabolic and endocrine conditions and medications prescribed for patients with at least 1 ambulatory visit at a site participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.
- **Table 10.** Overlap between with diagnosis codes for obesity and overweight and medications prescribed for patients with at least 1 ambulatory visit at a site participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.

Limitations:

Data presented are descriptive and derived from diagnosis and procedure codes collected in the electronic health record (EHR) during health care encounters. Rows and percentages may not add up to a total due to missing values and/or if counts are less than 10. If counts are between 1-10, then they are reported as “-” to protect patient privacy and risk of identification from aggregate values as outlined in the [Data Privacy Statement for PCORnet®](#).

No inferential analyses were conducted to compare populations or test hypotheses, as these are descriptive data only. Limitations with any EHR data analysis are applicable to this data, including the possibility for misclassification due to imperfect algorithms and lack of consistent definition of enrollment to define cohorts, in addition to limitations associated with processes to collect clinical data during health care encounters, including collection of demographic information. Data should be interpreted with these limitations in mind.

To ensure PCORnet data resources are of high quality for research and to mitigate the limitations above, all PCORnet-accessible data resources undergo [rigorous quality curation](#) and screening as part of quarterly coordinated data quality assessment. For more information on data curation activities and strategies to improve data quality for PCORnet, please contact frontdoor@pcornet.org.

Disclaimer:

PCORnet® is intended to improve the nation’s capacity to efficiently conduct patient-centered health research, particularly CER, by providing a large, highly representative network of health data, research expertise, and patient insights. PCORnet has been developed with funding from the Patient-Centered Outcomes Research Institute® (PCORI®).

Network queries that return only aggregate or limited data sets are covered by [the PCORnet® Master Data Sharing Agreement](#) (version 4.0), and site-level blanket Institutional Review Board approvals. The statements presented in this report do not necessarily represent the views of PCORI or other organizations participating in, collaborating with, or funding PCORnet.

For questions, comments, or suggestions related to this PCORnet® Front Door query or other PCORnet queries, please contact frontdoor@pcornet.org.

Tables

Table 1. Demographic characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.^{1,2}

	Total Patients with Ambulatory Visits		Type 2 Diabetes		Type 1 Diabetes		Prediabetes		Impaired Fasting Glucose		Gestational Diabetes		Thyroid Disorder		Parathyroid Disorder		Bone Density Structure Disorder		Osteoporosis	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	41,619,147	100	4,233,764	10.2	312,005	0.7	2,248,513	5.4	562,360	1.4	119,333	0.3	2,768,310	6.7	411,044	1.0	1,360,394	3.3	1,301,988	3.1
MEAN AGE (SD)	41.4 (± 22.2)		63.0 (± 13.7)		41.6 (± 19.1)		57.6 (± 15.7)		62.7 (± 14.3)		33.4 (± 6.0)		60.5 (± 17.4)		64.8 (± 15.6)		68.3 (± 13.4)		72.1 (± 11.0)	
AGE																				
Children 0-9	5,728,313	13.8	4,793	0.1	12,452	4.0	6,370	0.3	437	0.1	103	0.1	25,051	0.9	3,153	0.8	12,993	1.0	1,032	0.1
Children 10-19	5,261,433	12.6	30,985	0.7	54,816	17.6	64,116	2.9	4,847	0.9	774	0.6	55,076	2.0	5,150	1.3	22,105	1.6	3,932	0.3
Adults 20-34	6,238,851	15.0	133,912	3.2	63,716	20.4	147,340	6.6	23,903	4.3	67,104	56.2	208,047	7.5	14,240	3.5	16,208	1.2	8,745	0.7
Adults 35-54	9,436,246	22.7	917,941	21.7	80,776	25.9	646,777	28.8	124,267	22.1	50,869	42.6	629,814	22.8	69,157	16.8	86,401	6.4	52,631	4.0
Adults 55-64	5,428,902	13.0	1,027,178	24.3	42,320	13.6	524,499	23.3	119,991	21.3	327	0.3	526,336	19.0	77,747	18.9	228,933	16.8	179,629	13.8
Adults 65-74	5,417,608	13.0	1,179,001	27.8	36,601	11.7	518,663	23.1	164,773	29.3	108	0.1	661,456	23.9	117,095	28.5	554,360	40.7	507,240	39.0
Adults 75+	4,107,794	9.9	939,954	22.2	21,324	6.8	340,748	15.2	124,142	22.1	48	<0.1	662,530	23.9	124,502	30.3	439,394	32.3	548,779	42.1
SEX																				
Female	23,604,084	56.7	2,198,529	51.9	157,485	50.5	1,357,272	60.4	307,783	54.7	119,333	99.1	2,101,456	75.9	263,340	64.1	1,177,619	86.6	1,162,185	89.3
Male	17,996,578	43.2	2,034,601	48.1	154,446	49.5	890,797	39.6	254,507	45.3	0	0.0	666,410	24.1	147,666	35.9	182,643	13.4	139,691	10.7
Unknown	14,416	<0.1	433	<0.1	54	<0.1	269	<0.1	40	<0.1	138	0.1	296	<0.1	24	<0.1	81	<0.1	64	<0.1
Missing ³	4,069	<0.1	201	<0.1	20	<0.1	175	<0.1	30	<0.1			148	<0.1	14	<0.1	51	<0.1	48	<0.1
RACE																				
White	26,141,642	62.8	2,552,384	60.3	215,929	69.2	1,284,215	57.1	447,917	79.6	63,455	53.2	2,102,866	76.0	250,152	60.9	1,033,837	76.0	999,541	76.8
Black or African American	6,086,360	14.6	887,946	21.0	48,679	15.6	453,025	20.1	44,938	8.0	17,301	14.5	242,103	8.7	101,392	24.7	145,038	10.7	107,262	8.2
Asian	1,800,266	4.3	185,369	4.4	7,158	2.3	130,919	5.8	24,005	4.3	11,722	9.8	108,398	3.9	12,644	3.1	52,198	3.8	60,841	4.7
Multiple races	250,055	0.6	34,306	0.8	1,829	0.6	16,161	0.7	2,189	0.4	956	0.8	13,800	0.5	2,171	0.5	5,512	0.4	4,936	0.4
American Indian or Alaska Native	472,134	1.1	31,753	0.7	3,624	1.2	19,079	0.8	3,883	0.7	1,382	1.2	19,823	0.7	3,467	0.8	8,673	0.6	8,616	0.7
Native Hawaiian or Other Pacific Islander	98,024	0.2	13,444	0.3	721	0.2	6,367	0.3	987	0.2	535	0.4	3,984	0.1	1,177	0.3	1,652	0.1	1,493	0.1
Unknown	4,781,735	11.5	372,913	8.8	24,911	8.0	236,730	10.5	26,249	4.7	18,165	15.2	188,837	6.8	28,482	6.9	73,866	5.4	74,833	5.7
Missing ³	1,988,931	4.8	155,649	3.7	9,154	2.9	102,017	4.5	12,192	2.2	5,817	4.9	88,499	3.2	11,559	2.8	39,618	2.9	44,466	3.4
HISPANIC																				
No	29,345,387	70.5	3,124,222	73.8	243,036	77.9	1,610,166	71.6	481,402	85.6	75,050	62.9	2,206,443	79.7	338,553	82.4	1,135,145	83.4	1,081,139	83.0
Yes	6,296,346	15.1	663,570	15.7	35,097	11.2	402,544	17.9	40,762	7.2	29,872	25.0	283,616	10.2	41,559	10.1	116,552	8.6	105,048	8.1
Unknown	2,969,300	7.1	213,564	5.0	17,226	5.5	104,181	4.6	20,273	3.6	6,276	5.3	136,017	4.9	15,734	3.8	51,566	3.8	51,800	4.0
Missing ³	3,008,114	7.2	232,408	5.5	16,646	5.3	131,622	5.9	19,923	3.5	8,135	6.8	142,234	5.1	15,198	3.7	57,131	4.2	64,001	4.9

¹Total only includes 71 data-contributing partners in PCORnet.

²Some totals may not add up due to masking low cell sizes.

³Missing includes those values that are null, refuse to answer, and no information.

Table 2. Demographic characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.^{1,2}

	Total Patients with Ambulatory Visits		Hypertension		Hypercholesterolemia		Pure Hypertriglyceridemia		Polycystic Ovary Syndrome (PCOS)		Steatohepatitis (MASH)		HDL Deficiency		Metabolic Syndrome as designated by ICD-10 Code	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	41,619,147	100	9,974,076	24.0	9,587,923	23.0	478,141	1.1	307,682	0.7	137,071	0.3	73,629	0.2	71,013	0.2
MEAN AGE (SD)	41.4 (± 22.2)		63.4 (± 14.6)		62.7 (± 14.2)		48.5 (± 17.1)		32.2 (± 9.1)		57.5 (± 14.8)		43.1 (± 17.5)		51.7 (± 15.7)	
AGE																
Children 0-9	5,728,313	13.8	28,724	0.3	15,295	0.2	8,943	1.9	27,845	9.0	3,960	2.9	1,844	2.5	404	0.6
Children 10-19	5,261,433	12.6	70,765	0.7	133,725	1.4	58,049	12.1	164,467	53.5	8,423	6.1	15,288	20.8	3,917	5.5
Adults 20-34	6,238,851	15.0	333,133	3.3	350,137	3.7	43,600	9.1	108,201	35.2	36,789	26.8	9,402	12.8	7,995	11.3
Adults 35-54	9,436,246	22.7	2,117,315	21.2	2,026,547	21.1	162,361	34.0	5,609	1.8	35,523	25.9	21,920	29.8	24,888	35.0
Adults 55-64	5,428,902	13.0	2,240,105	22.5	2,183,488	22.8	92,423	19.3	1,264	0.4	36,282	26.5	10,741	14.6	15,061	21.2
Adults 65-74	5,417,608	13.0	2,726,194	27.3	2,680,071	28.0	73,243	15.3	275	0.1	15,812	11.5	9,201	12.5	12,710	17.9
Adults 75+	4,107,794	9.9	2,457,840	24.6	2,198,660	22.9	39,522	8.3	27,845	9.0	3,960	2.9	5,233	7.1	6,038	8.5
SEX																
Female	23,604,084	56.7	5,244,062	52.6	5,071,470	52.9	217,710	45.5	307,169	99.8	78,877	57.5	30,696	41.7	44,274	62.3
Male	17,996,578	43.2	4,728,605	47.4	4,514,974	47.1	260,316	54.4	0	0.0	58,173	42.4	42,917	58.3	26,732	37.6
Unknown	14,416	<0.1	939	<0.1	957	<0.1	77	0.1	469	0.2	-	<0.1	-	<0.1	-	<0.1
Missing ³	4,069	<0.1	470	<0.1	522	<0.1	38	<0.1	44	<0.1	-	<0.1	-	<0.1	-	<0.1
RACE																
White	26,141,642	62.8	6,598,373	66.2	6,642,487	69.3	321,755	67.3	190,408	61.9	103,181	75.3	47,168	64.1	48,198	67.9
Black or African American	6,086,360	14.6	1,886,316	18.9	1,334,212	13.9	37,776	7.9	43,374	14.1	8,133	5.9	9,568	13.0	10,550	14.9
Asian	1,800,266	4.3	333,525	3.3	406,000	4.2	28,407	5.9	16,500	5.4	5,068	3.7	3,875	5.3	2,643	3.7
Multiple races	250,055	0.6	56,849	0.6	50,558	0.5	3,702	0.8	2,206	0.7	1,098	0.8	510	0.7	457	0.6
American Indian or Alaska Native	472,134	1.1	69,439	0.7	68,241	0.7	4,851	1.0	3,952	1.3	932	0.7	942	1.3	536	0.8
Native Hawaiian or Other Pacific Islander	98,024	0.2	21,013	0.2	18,149	0.2	1,423	0.3	856	0.3	292	0.2	204	0.3	147	0.2
Unknown	4,781,735	11.5	686,937	6.9	707,239	7.4	61,323	12.8	33,030	10.7	13,105	9.6	9,038	12.3	5,231	7.4
Missing ³	1,988,931	4.8	321,624	3.2	361,037	3.8	18,904	4.0	17,356	5.6	5,262	3.8	2,324	3.2	3,251	4.6
HISPANIC																
No	29,345,387	70.5	7,865,522	78.0	7,453,086	77.7	309,274	64.7	213,829	69.5	98,719	72.0	49,594	67.4	54,435	76.7
Yes	6,296,346	15.1	1,064,286	10.7	1,135,607	11.8	116,677	24.4	55,757	18.1	25,797	18.8	18,020	24.5	10,233	14.4
Unknown	2,969,300	7.1	522,286	5.2	473,889	4.9	21,304	4.5	16,680	5.4	6,281	4.6	3,030	4.1	2,669	3.8
Missing ³	3,008,114	7.2	521,982	5.2	525,341	5.5	30,886	6.5	21,416	7.0	6,274	4.6	2,985	4.1	3,676	5.2

¹Total only includes 71 data-contributing partners in PCORnet.

²Some totals may not add up due to masking low cell sizes.

³Missing includes those values that are null, refuse to answer, and no information.

Table 3. Demographic characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to overweight or obesity between January 1, 2020 – December 31, 2024.^{1,2}

	Total Patients with Ambulatory Visits		Adults								Pediatrics					
			Overweight Adults		Obese Class 1 Adults		Obese Class 2 Adults		Obese Class 3 Adults		Overweight		Obesity		Severe Obesity	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	41,619,147	100	1,226,632	2.9	2,183,634	5.2	1,552,207	3.7	1,521,251	3.7	431,363	1.0	498,574	1.2	10,472	<0.1
MEAN AGE (SD)	41.4 (± 22.2)		55.8 (± 16.2)		55.4 (± 15.3)		53.9 (± 14.8)		50.6 (± 14.6)		10.7 (± 4.8)		11.6 (± 4.1)		12.2 (± 3.9)	
AGE																
Children 0-9	5,728,313	13.8									177,096	41.1	159,885	32.1	2,659	25.4
Children 10-19	5,261,433	12.6									254,267	58.9	338,689	67.9	7,813	74.6
Adults 20-34	6,238,851	15.0	172,385	14.1	274,705	12.6	215,703	13.9	276,790	18.2						
Adults 35-54	9,436,246	22.7	375,666	30.6	725,563	33.2	551,826	35.6	615,050	40.4						
Adults 55-64	5,428,902	13.0	248,072	20.2	468,001	21.4	332,244	21.4	303,511	20.0						
Adults 65-74	5,417,608	13.0	247,493	20.2	445,528	20.4	297,941	19.2	232,544	15.3						
Adults 75+	4,107,794	9.9	183,016	14.9	269,837	12.4	154,493	10.0	93,356	6.1						
SEX																
Female	23,604,084	56.7	695,660	56.7	1,301,010	59.6	1,000,033	64.4	1,069,070	70.3	223,328	51.8	240,875	48.3	5,085	48.6
Male	17,996,578	43.2	530,807	43.3	882,284	40.4	551,932	35.6	451,911	29.7	208,001	48.2	257,640	51.7	5,387	51.4
Unknown	14,416	<0.1	101	<0.1	214	<0.1	165	<0.1	193	<0.1	-	<0.1	43	<0.1	0	0.0
Missing ³	4,069	<0.1	64	<0.1	126	<0.1	77	<0.1	77	<0.1	-	<0.1	16	<0.1	0	0.0
RACE																
White	26,141,642	62.8	840,225	68.5	1,452,130	66.5	1,017,495	65.6	970,254	63.8	205,694	47.7	227,023	45.5	4,480	42.8
Black or African American	6,086,360	14.6	185,929	15.2	398,260	18.2	333,698	21.5	379,523	24.9	98,862	22.9	129,890	26.1	2,867	27.4
Asian	1,800,266	4.3	43,617	3.6	45,986	2.1	19,404	1.3	11,539	0.8	25,473	5.9	15,164	3.0	203	1.9
Multiple races	250,055	0.6	9,107	0.7	16,197	0.7	11,912	0.8	12,818	0.8	3,327	0.8	4,072	0.8	72	0.7
American Indian or Alaska Native	472,134	1.1	5,121	0.4	10,705	0.5	8,128	0.5	9,508	0.6	9,144	2.1	9,356	1.9	297	2.8
Native Hawaiian or Other Pacific Islander	98,024	0.2	4,483	0.4	6,706	0.3	5,409	0.3	6,067	0.4	1,771	0.4	2,832	0.6	45	0.4
Unknown	4,781,735	11.5	114,292	9.3	182,849	8.4	114,914	7.4	99,543	6.5	75,700	17.5	95,325	19.1	2,191	20.9
Missing ³	1,988,931	4.8	23,858	1.9	70,801	3.2	41,247	2.7	31,999	2.1	11,392	2.6	14,912	3.0	317	3.0
HISPANIC																
No	29,345,387	70.5	902,984	73.6	1,618,797	74.1	1,182,885	76.2	1,194,443	78.5	253,727	58.8	281,719	56.5	6,052	57.8
Yes	6,296,346	15.1	224,598	18.3	361,420	16.6	226,393	14.6	188,693	12.4	131,908	30.6	161,771	32.4	3,354	32.0
Unknown	2,969,300	7.1	54,753	4.5	99,770	4.6	70,449	4.5	70,089	4.6	23,991	5.6	26,307	5.3	674	6.4
Missing ³	3,008,114	7.2	44,297	3.6	103,647	4.7	72,480	4.7	68,026	4.5	21,737	5.0	28,777	5.8	392	3.7

¹Total only includes 71 data-contributing partners in PCORnet.

²Some totals may not add up due to masking low cell sizes.

³Missing includes those values that are null, refuse to answer, and no information.

Table 4. Geographic and care setting characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.^{1,2}

	Total Patients with Ambulatory Visits		Type 2 Diabetes		Type 1 Diabetes		Prediabetes		Impaired Fasting Glucose		Gestational Diabetes		Thyroid Disorder		Parathyroid Disorder		Bone Density Structure Disorder		Osteoporosis	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	41,619,147	100	4,233,764	10.2	312,005	0.7	2,248,513	5.4	562,360	1.4	119,333	0.3	2,768,310	6.7	411,044	1.0	1,360,394	3.3	1,301,988	3.1
AREA DEPRIVATION INDEX (ADI) QUARTILE BASED ON 5-DIGIT ZIP²																				
ADI Quartile 1 (Higher SES)	15,176,216	36.5	1,174,784	27.7	109,355	35.0	773,774	34.4	243,004	43.2	37,395	31.3	1,051,772	38.0	130,546	31.8	568,126	41.8	541,820	41.6
ADI Quartile 2	7,545,671	18.1	783,441	18.5	59,527	19.1	390,810	17.4	124,992	22.2	21,652	18.1	533,963	19.3	77,646	18.9	248,082	18.2	236,918	18.2
ADI Quartile 3	8,632,038	20.7	1,022,269	24.1	68,889	22.1	455,637	20.3	117,363	20.9	27,262	22.8	599,895	21.7	89,617	21.8	264,739	19.5	256,042	19.7
ADI Quartile 4 (Lower SES)	6,795,354	16.3	938,086	22.2	50,418	16.2	414,944	18.5	53,725	9.6	23,478	19.7	384,919	13.9	76,523	18.6	182,196	13.4	166,180	12.8
Missing	3,469,868	8.3	315,184	7.4	23,816	7.6	213,348	9.5	23,276	4.1	9,546	8.0	197,761	7.1	36,712	8.9	97,251	7.1	101,028	7.8
RURAL-URBAN COMMUTING AREA (RUCA) CODES BASED ON 5-DIGIT ZIP³																				
Metropolitan/Urban Areas	33,083,567	79.5	3,298,486	77.9	243,382	78.0	1,818,035	80.9	437,206	77.7	95,459	80.0	2,162,278	78.1	320,986	78.1	1,090,257	80.1	1,028,091	79.0
Micropolitan/Large Rural Areas	3,199,064	7.7	393,280	9.3	27,801	8.9	144,523	6.4	58,144	10.3	9,238	7.7	251,917	9.1	33,335	8.1	106,593	7.8	107,729	8.3
Small Towns	1,316,322	3.2	162,427	3.8	11,871	3.8	54,578	2.4	26,651	4.7	3,687	3.1	107,838	3.9	15,072	3.7	46,703	3.4	44,929	3.5
Isolated Rural Area	886,585	2.1	104,456	2.5	7,729	2.5	37,660	1.7	21,213	3.8	2,109	1.8	74,373	2.7	8,909	2.2	32,458	2.4	32,119	2.5
Missing	3,133,609	7.5	275,115	6.5	21,226	6.8	193,717	8.6	19,146	3.4	8,840	7.4	171,904	6.2	32,749	8.0	84,383	6.2	89,120	6.8
CARE SETTING																				
Ambulatory Visit	41,619,147	100.0	4,233,764	100.0	312,005	100.0	2,248,513	100.0	562,360	100.0	119,333	100.0	2,768,310	100.0	411,044	100.0	1,360,394	100.0	1,301,988	100.0
Emergency Department Visit	5,047,704	12.1	796,087	18.8	58,746	18.8	283,074	12.6	72,113	12.8	23,053	19.3	449,300	16.2	96,555	23.5	216,796	15.9	222,800	17.1
ED to Inpatient Hospital Stay	791,653	1.9	267,862	6.3	20,674	6.6	61,650	2.7	13,511	2.4	3,037	2.5	142,367	5.1	41,935	10.2	60,657	4.5	79,255	6.1
Inpatient Hospital Stay	2,242,138	5.4	476,595	11.3	36,161	11.6	127,606	5.7	27,167	4.8	40,053	33.6	287,827	10.4	73,813	18.0	113,654	8.4	129,519	9.9
Institutional Stay	77,342	0.2	16,737	0.4	1,128	0.4	4,939	0.2	1,316	0.2	325	0.3	11,239	0.4	2,978	0.7	5,651	0.4	7,288	0.6
Observational Stay	407,693	1.0	89,136	2.1	7,666	2.5	27,662	1.2	6,786	1.2	2,795	2.3	51,474	1.9	15,267	3.7	26,176	1.9	25,504	2.0
Telehealth Visit	5,735,469	13.8	857,081	20.2	79,703	25.5	605,862	26.9	119,164	21.2	36,951	31.0	641,601	23.2	116,821	28.4	319,328	23.5	315,515	24.2

¹Total only includes 71 data-contributing partners in PCORnet.

²Area Deprivation Index (ADI): Patient 5-Digit Zip Codes are mapped to socioeconomic status by normalized Area Deprivation Index (ADI) value (0-100). Lower values are associated with higher socioeconomic status (SES) and higher values are associated with lower SES. A ranking of 1 indicates the highest level of SES within the nation and an ADI with a ranking of 100 indicates the lowest level of SES. In this table, values are grouped into quartiles using the count of zip codes. Quartile 1 (Higher SES) represents the lowest range of ADI values and Quartile 4 (Lowest SES) represents the highest range of ADI values (Q1=0-38, Q2=39-43, Q3=44-49, and Q4=50-100). For additional information regarding the ADI index, see the Neighborhood Atlas here: <https://www.neighborhoodatlas.medicine.wisc.edu/>. Note that the Area Deprivation Index (ADI) is designed for validity at the 9-digit zip or census block group level rather than the 5-digit zip level. Some zip codes do not map to an ADI value.

³Represented as combined [Rural Urban Commuting Area \(RUCA\) codes](https://hcup-us.ahrq.gov/db/vars/siddistnote.jsp?var=pl_ruca4) as referenced on https://hcup-us.ahrq.gov/db/vars/siddistnote.jsp?var=pl_ruca4. RUCA contains 10 primary and 21 secondary codes which delineate components of rural and urban areas and define county-level metropolitan (urban) and nonmetropolitan areas (i.e., micropolitan/large rural areas, small towns and isolated rural areas).

Table 5. Geographic and care setting characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.^{1 2}

	Total Patients with Ambulatory Visits		Hypertension		Hypercholesterolemia		Pure Hypertriglyceridemia		Polycystic Ovary Syndrome (PCOS)		Steatohepatitis (MASH)		HDL Deficiency		Metabolic Syndrome as designated by ICD-10 Code	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	41,619,147	100	9,974,076	24.0	9,587,923	23.0	478,141	1.1	307,682	0.7	137,071	0.3	73,629	0.2	71,013	0.2
AREA DEPRIVATION INDEX (ADI) QUARTILE BASED ON 5-DIGIT ZIP²																
ADI Quartile 1 (Higher SES)	15,176,216	36.5	3,216,527	32.2	3,486,655	36.4	158,607	33.2	108,560	35.3	42,362	30.9	26,604	36.1	26,537	37.4
ADI Quartile 2	7,545,671	18.1	1,872,671	18.8	1,771,384	18.5	87,866	18.4	60,289	19.6	27,542	20.1	13,176	17.9	13,385	18.8
ADI Quartile 3	8,632,038	20.7	2,301,300	23.1	2,048,047	21.4	104,243	21.8	67,132	21.8	32,677	23.8	15,068	20.5	14,185	20.0
ADI Quartile 4 (Lower SES)	6,795,354	16.3	1,870,481	18.8	1,567,528	16.3	93,808	19.6	48,924	15.9	24,846	18.1	13,489	18.3	11,583	16.3
Missing	3,469,868	8.3	713,097	7.1	714,309	7.5	33,617	7.0	22,777	7.4	9,644	7.0	5,292	7.2	5,323	7.5
RURAL-URBAN COMMUTING AREA (RUCA) CODES BASED ON 5-DIGIT ZIP³																
Metropolitan/Urban Areas	33,083,567	79.5	7,765,850	77.9	7,565,251	78.9	388,482	81.2	251,334	81.7	105,036	76.6	61,253	83.2	57,655	81.2
Micropolitan/Large Rural Areas	3,199,064	7.7	927,026	9.3	817,272	8.5	35,511	7.4	21,849	7.1	14,023	10.2	4,730	6.4	4,204	5.9
Small Towns	1,316,322	3.2	393,971	3.9	339,409	3.5	14,145	3.0	8,554	2.8	5,958	4.3	1,732	2.4	2,776	3.9
Isolated Rural Area	886,585	2.1	268,774	2.7	238,945	2.5	9,825	2.1	5,192	1.7	3,691	2.7	1,098	1.5	1,615	2.3
Missing	3,133,609	7.5	618,455	6.2	627,046	6.5	30,178	6.3	20,753	6.7	8,363	6.1	4,816	6.5	4,763	6.7
CARE SETTING																
Ambulatory Visit	41,619,147	100.0	9,974,076	100.0	9,587,923	100.0	478,141	100.0	307,682	100.0	137,071	100.0	73,629	100.0	71,013	100.0
Emergency Department (ED) Visit	5,047,704	12.1	1,765,557	17.7	1,399,502	14.6	62,983	13.2	51,062	16.6	28,332	20.7	8,541	11.6	11,987	16.9
ED to Inpatient Hospital Stay	791,653	1.9	533,106	5.3	432,799	4.5	15,744	3.3	5,146	1.7	11,371	8.3	1,432	1.9	3,077	4.3
Inpatient Hospital Stay	2,242,138	5.4	1,031,292	10.3	826,345	8.6	30,694	6.4	24,266	7.9	20,768	15.2	2,975	4.0	6,757	9.5
Institutional Stay	77,342	0.2	37,702	0.4	30,214	0.3	1,535	0.3	931	0.3	610	0.4	152	0.2	206	0.3
Observational Stay	407,693	1.0	195,593	2.0	159,434	1.7	6,512	1.4	3,741	1.2	3,614	2.6	849	1.2	1,444	2.0
Telehealth Visit	5,735,469	13.8	1,882,175	18.9	1,976,385	20.6	128,162	26.8	99,457	32.3	41,879	30.6	21,028	28.6	24,601	34.6

¹Total only includes 71 data-contributing partners in PCORnet.

²Area Deprivation Index (ADI): Patient 5-Digit Zip Codes are mapped to socioeconomic status by normalized Area Deprivation Index (ADI) value (0-100). Lower values are associated with higher socioeconomic status (SES) and higher values are associated with lower SES. A ranking of 1 indicates the highest level of SES within the nation and an ADI with a ranking of 100 indicates the lowest level of SES. In this table, values are grouped into quartiles using the count of zip codes. Quartile 1 (Higher SES) represents the lowest range of ADI values and Quartile 4 (Lowest SES) represents the highest range of ADI values (Q1=0-38, Q2=39-43, Q3=44-49, and Q4=50-100). For additional information regarding the ADI index, see the Neighborhood Atlas here: <https://www.neighborhoodatlas.medicine.wisc.edu/>. Note that the Area Deprivation Index (ADI) is designed for validity at the 9-digit zip or census block group level rather than the 5-digit zip level.

Represented as combined [Rural Urban Commuting Area \(RUCA\) codes](#) as referenced on https://hcup-us.ahrq.gov/db/vars/siddistnote.jsp?var=pl_ruca4. RUCA contains 10 primary and 21 secondary codes which delineate components of rural and urban areas and define county-level metropolitan (urban) and nonmetropolitan areas (i.e., micropolitan/large rural areas, small towns and isolated rural areas).

Table 6. Geographic and care setting characteristics of the patient population with at least 1 ambulatory visit across sites participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to overweight or obesity metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.^{1,2}

	Total Patients with Ambulatory Visits		Adults								Pediatrics					
			Overweight Adults		Obese Class 1 Adults		Obese Class 2 Adults		Adult Obese Class 3		Overweight		Obesity		Severe Obesity	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
UNIQUE PATIENT RECORDS	41,619,147	100	1,226,632	2.9	2,183,634	5.2	1,552,207	3.7	1,521,251	3.7	431,363	1.0	498,574	1.2	10,472	<0.1
AREA DEPRIVATION INDEX (ADI) QUARTILE BASED ON 5-DIGIT ZIP²																
ADI Quartile 1 (Higher SES)	15,176,216	36.5	389,628	31.8	697,686	32.0	447,826	28.9	385,657	25.4	146,306	33.9	132,529	26.6	2,678	25.6
ADI Quartile 2	7,545,671	18.1	208,391	17.0	404,459	18.5	303,803	19.6	313,497	20.6	68,995	16.0	89,390	17.9	1,929	18.4
ADI Quartile 3	8,632,038	20.7	258,782	21.1	489,830	22.4	378,172	24.4	399,328	26.2	79,869	18.5	115,812	23.2	2,445	23.3
ADI Quartile 4 (Lower SES)	6,795,354	16.3	227,716	18.6	418,888	19.2	317,375	20.4	334,538	22.0	102,577	23.8	129,536	26.0	2,935	28.0
Missing	3,469,868	8.3	142,115	11.6	172,771	7.9	105,031	6.8	88,231	5.8	33,616	7.8	31,307	6.3	485	4.6
RURAL-URBAN COMMUTING AREA (RUCA) CODES BASED ON 5-DIGIT ZIP³																
Metropolitan/Urban Areas	33,083,567	79.5	933,233	76.1	1,728,886	79.2	1,224,120	78.9	1,178,276	77.5	366,718	85.0	417,062	83.7	8,957	85.5
Micropolitan/Large Rural Areas	3,199,064	7.7	104,650	8.5	184,109	8.4	143,728	9.3	159,871	10.5	23,394	5.4	35,210	7.1	674	6.4
Small Towns	1,316,322	3.2	38,129	3.1	72,579	3.3	57,609	3.7	66,569	4.4	5,027	1.2	10,272	2.1	269	2.6
Isolated Rural Area	886,585	2.1	23,265	1.9	46,606	2.1	36,614	2.4	41,809	2.7	3,959	0.9	6802.00	1.4	145	1.4
Missing	3,133,609	7.5	127,355	10.4	151,454	12.3	90,136	7.3	74,726	6.1	32,265	2.6	29,228	2.4	427	<0.1
CARE SETTING																
Ambulatory Visit	41,619,147	100.0	1,226,632	100.0	2,183,634	100.0	1,552,207	100.0	1,521,251	100.0	431,363	100.0	498,574	100.0	10,472	100.0
Emergency Department (ED) Visit	5,047,704	12.1	190,282	15.5	368,939	16.9	288,753	18.6	301,944	19.8	45,822	10.6	68,228	13.7	1,832	17.5
ED to Inpatient Hospital Stay	791,653	1.9	75,890	6.2	118,847	5.4	82,243	5.3	75,453	5.0	1,697	0.4	3,348	0.7	111	1.1
Inpatient Hospital Stay	2,242,138	5.4	131,888	10.8	250,623	11.5	176,942	11.4	160,930	10.6	9,349	2.2	14,809	3.0	626	6.0
Institutional Stay	77,342	0.2	3,807	0.3	7,816	0.4	5,757	0.4	5,096	0.3	544	0.1	1,619	0.3	100	1.0
Observational Stay	407,693	1.0	23,859	1.9	43,939	2.0	32,196	2.1	29,435	1.9	1,852	0.4	5,078	1.0	191	1.8
Telehealth Visit	5,735,469	13.8	280,456	22.9	549,274	25.2	407,490	26.3	410,647	27.0	41,823	9.7	60,558	12.1	2,270	21.7

¹Total only includes 71 data-contributing partners in PCORnet.

²Area Deprivation Index (ADI): Patient 5-Digit Zip Codes are mapped to socioeconomic status by normalized Area Deprivation Index (ADI) value (0-100). Lower values are associated with higher socioeconomic status (SES) and higher values are associated with lower SES. A ranking of 1 indicates the highest level of SES within the nation and an ADI with a ranking of 100 indicates the lowest level of SES. In this table, values are grouped into quartiles using the count of zip codes. Quartile 1 (Higher SES) represents the lowest range of ADI values and Quartile 4 (Lowest SES) represents the highest range of ADI values (Q1=0-38, Q2=39-43, Q3=44-49, and Q4=50-100). For additional information regarding the ADI index, see the Neighborhood Atlas here: <https://www.neighborhoodatlas.medicine.wisc.edu/>. Note that the Area Deprivation Index (ADI) is designed for validity at the 9-digit zip or census block group level rather than the 5-digit zip level.

Represented as combined [Rural Urban Commuting Area \(RUCA\) codes](#) as referenced on https://hcup-us.ahrq.gov/db/vars/siddistnote.jsp?var=pl_ruca4. RUCA contains 10 primary and 21 secondary codes which delineate components of rural and urban areas and define county-level metropolitan (urban) and nonmetropolitan areas (i.e., micropolitan/large rural areas, small towns and isolated rural areas).

Table 7. Medications prescribed related to metabolic and endocrine conditions for patients with at least 1 ambulatory visit at a site participating in PCORnet between January 1, 2024 – December 31, 2024.¹

	Total Patients with Ambulatory Visits		Thyroid Replacement Therapy		Anti-thyroid Medications		Anti-hypertensives		Hormonal Therapies Containing Estrogen		Insulin		Metformin		Other Diabetes Medications		SGLT-2 Inhibitors		GLP-1 Agonists		Non-GLP-1 Anti-obesity Agent		Osteoporosis Medications	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Number of unique patients	41,619,147	100	1,296,629	3.1	55,888	0.1	7,688,502	18.5	1,294,890	3.1	1,193,124	2.9	1,619,736	3.9	581,737	1.4	792,239	1.9	1,352,309	3.2	222,160	0.5	409,099	1.0
By Age (N)																								
Mean, StdDev	41.4	22.2	60.1	17.6	53.6	18.3	61.2	16.3	42.8	18.7	59	16.9	58.7	15.2	64.5	12.7	63.7	12.8	54.1	13.9	46.2	14	71.8	10.5
Children 0-9	5,728,313	13.8	12,654	1.0	419	0.7	91,808	1.2	3,099	0.2	10,490	0.9	919	0.1	59	<0.1	236	<0.1	82	<0.1	666	0.3	261	0.1
Children 10-19	5,261,433	12.6	30,165	2.3	2,845	5.1	106,658	1.4	149,038	11.5	44,599	3.7	26,931	1.7	618	0.1	1,934	0.2	16,526	1.2	5,880	2.6	794	0.2
Adults 20-34	6,238,851	15.0	90,801	7.0	7,536	13.5	429,216	5.6	392,697	30.3	85,964	7.2	104,779	6.5	10,466	1.8	16,492	2.1	121,110	9.0	43,369	19.5	1,703	0.4
Adults 35-54	9,436,246	22.7	292,068	22.5	16,442	29.4	1,682,681	21.9	355,412	27.4	258,434	21.7	437,271	27.0	115,293	19.8	163,502	20.6	512,618	37.9	105,779	47.6	16,176	4.0
Adults 55-64	5,428,902	13.0	258,098	19.9	9,813	17.6	1,661,583	21.6	179,540	13.9	260,965	21.9	412,236	25.5	147,144	25.3	209,643	26.5	351,890	26.0	39,898	18.0	59,161	14.5
Adults 65-74	5,417,608	13.0	311,599	24.0	10,044	18.0	1,970,524	25.6	130,812	10.1	297,216	24.9	402,068	24.8	171,273	29.4	228,631	28.9	255,406	18.9	20,891	9.4	165,594	40.5
Adults 75+	4,107,794	9.9	301,244	23.2	8,789	15.7	1,746,032	22.7	84,292	6.5	235,456	19.7	235,532	14.5	136,884	23.5	171,801	21.7	94,677	7.0	5,677	2.6	165,410	40.4
METABOLIC and ENDOCRINE CONDITIONS																								
Bone Density Structure Disorder	1,360,394	3.3	148,325	11.4	4,636	8.3	569,889	7.4	87,581	6.8	73,330	6.1	96,818	6.0	38,012	6.5	50,910	6.4	69,935	5.2	9,011	4.1	137,369	33.6
Osteoporosis	1,301,988	3.1	146,562	11.3	5,111	9.1	556,514	7.2	72,072	5.6	77,501	6.5	77,293	4.8	35,282	6.1	47,076	5.9	49,911	3.7	6,623	3.0	299,197	73.1
Thyroid Disorder	2,768,310	6.7	1,025,137	79.1	50,110	89.7	1,057,643	13.8	140,600	10.9	203,084	17.0	222,907	13.8	84,108	14.5	116,473	14.7	205,746	15.2	32,407	14.6	93,325	22.8
Parathyroid Disorder	411,044	1.0	52,386	4.0	2,143	3.8	233,763	3.0	14,034	1.1	67,332	5.6	25,571	1.6	19,890	3.4	33,339	4.2	34,685	2.6	3,143	1.4	27,078	6.6
Impaired Fasting Glucose	562,360	1.4	48,478	3.7	1,326	2.4	265,741	3.5	21,504	1.7	8,902	0.7	37,386	2.3	3,558	0.6	10,862	1.4	42,336	3.1	9,375	4.2	17,877	4.4
Prediabetes	2,248,513	5.4	173,808	13.4	6,811	12.2	976,770	12.7	88,984	6.9	47,473	4.0	242,012	14.9	15,884	2.7	54,202	6.8	205,076	15.2	37,272	16.8	55,708	13.6
Diabetes - Type 1	312,005	0.7	26,640	2.1	1,112	2.0	97,456	1.3	8,156	0.6	191,337	16.0	25,778	1.6	8,738	1.5	14,567	1.8	26,487	2.0	1,612	0.7	4,001	1.0
Diabetes - Type 2	4,233,764	10.2	291,313	22.5	11,061	19.8	2,206,148	28.7	85,042	6.6	890,540	74.6	1,256,903	77.6	535,455	92.0	606,868	76.6	764,097	56.5	22,145	10.0	74,093	18.1
Gestational Diabetes	119,333	0.3	5,152	0.4	255	0.5	18,432	0.2	7,041	0.5	16,350	1.4	12,692	0.8	760	0.1	691	0.1	5,212	0.4	1,328	0.6	31	<0.1
Polycystic Ovary Syndrome (PCOS)	307,682	0.7	18,452	1.4	517	0.9	58,579	0.8	50,210	3.9	9,517	0.8	57,956	3.6	2,521	0.4	4,707	0.6	44,834	3.3	10,695	4.8	297	0.1
Steatohepatitis (MASH)	137,071	0.3	13,005	1.0	245	0.4	65,810	0.9	4,583	0.4	22,888	1.9	21,438	1.3	8,087	1.4	11,805	1.5	24,190	1.8	2,138	1.0	3,047	0.7
Hypertension	9,974,076	24.0	644,049	49.7	24,386	43.6	5,893,689	76.7	235,849	18.2	852,561	71.5	1,085,383	67.0	445,404	76.6	620,870	78.4	817,461	60.4	76,355	34.4	227,386	55.6
Pure Hypertriglyceridemia	478,141	1.1	29,593	2.3	733	1.3	187,603	2.4	16,484	1.3	42,287	3.5	74,872	4.6	26,124	4.5	33,931	4.3	55,659	4.1	5,727	2.6	6,263	1.5
HDL Deficiency	73,629	0.2	3,430	0.3	143	0.3	22,595	0.3	2,008	0.2	3,214	0.3	8,320	0.5	2,316	0.4	2,983	0.4	7,276	0.5	1,230	0.6	574	0.1
Hypercholesteremia	9,587,923	23.0	690,934	53.3	20,622	36.9	4,415,021	57.4	289,692	22.4	781,301	65.5	1,091,147	67.4	436,350	75.0	587,712	74.2	811,882	60.0	79,930	36.0	247,426	60.5
Metabolic Syndrome	71,013	0.2	6,241	0.5	143	0.3	30,680	0.4	3,655	0.3	6,279	0.5	15,175	0.9	2,142	0.4	4,712	0.6	20,292	1.5	4,112	1.9	856	0.2
Overweight - Adult	1,236,802	3.0	81,607	6.3	3,189	5.7	456,097	5.9	49,816	3.8	92,188	7.7	102,942	6.4	42,250	7.3	53,980	6.8	73,472	5.4	16,862	7.6	25,487	6.2
Obese Class 1 - Adult	2,200,939	5.3	148,582	11.5	5,216	9.3	921,069	12.0	87,561	6.8	180,929	15.2	245,066	15.1	82,496	14.2	120,835	15.3	280,496	20.7	53,922	24.3	32,100	7.8
Obese Class 2 - Adult	1,565,540	3.8	110,279	8.5	3,608	6.5	695,010	9.0	60,280	4.7	144,178	12.1	205,088	12.7	62,603	10.8	96,881	12.2	275,565	20.4	47,954	21.6	17,962	4.4
Obese Class 3 - Adult	1,537,951	3.7	108,132	8.3	3,237	5.8	673,795	8.8	55,461	4.3	140,784	11.8	215,904	13.3	56,260	9.7	91,184	11.5	331,633	24.5	54,564	24.6	12,027	2.9
Overweight - Child	435,593	1.0	1,790	0.1	122	0.2	5,155	0.1	7,850	0.6	2,281	0.2	1,484	0.1	74	<0.1	137	<0.1	697	0.1	323	0.1	45	<0.1
Obese - Child	508,602	1.2	5,120	0.4	233	0.4	14,374	0.2	12,377	1.0	5,976	0.5	13,890	0.9	256	<0.1	738	0.1	10,031	0.7	2,783	1.3	134	<0.1
Severely Obese - Child	10,975	<0.1	210	<0.1	13	<0.1	725	<0.1	353	<0.1	229	<0.1	1,107	0.1	34	<0.1	80	<0.1	1,094	0.1	305	0.1	-	<0.1
ADDITIONAL CONDITIONS																								
Cardiovascular Disease	10,885,856	26.2	690,775	53.3	26,053	46.6	6,123,217	79.6	256,992	19.8	897,637	75.2	1,119,978	69.1	458,395	78.8	660,382	83.4	846,530	62.6	80,699	36.3	247,801	60.6

Chronic Kidney Disease	2,594,518	6.2	203,507	15.7	6,504	11.6	1,442,723	18.8	50,080	3.9	424,454	35.6	280,587	17.3	167,217	28.7	268,190	33.9	224,344	16.6	12,967	5.8	65,918	16.1
Sleep Apnea	2,962,356	7.1	192,975	14.9	5,495	9.8	1,248,080	16.2	78,442	6.1	244,572	20.5	286,064	17.7	91,111	15.7	180,225	22.7	337,604	25.0	40,573	18.3	46,995	11.5
Breast Cancer	567,253	1.4	44,548	3.4	1,517	2.7	184,117	2.4	16,630	1.3	24,342	2.0	32,281	2.0	11,979	2.1	16,216	2.0	28,151	2.1	4,066	1.8	45,102	11.0
Dyslipidemia	9,869,158	23.7	702,685	54.2	21,005	37.6	4,488,583	58.4	300,207	23.2	792,415	66.4	1,116,837	69.0	443,319	76.2	595,649	75.2	832,736	61.6	83,646	37.7	249,695	61.0
Hyper- or Hypo- Glycemia	2,454,439	5.9	183,733	14.2	7,290	13.0	1,229,763	16.0	61,481	4.7	666,072	55.8	561,980	34.7	279,120	48.0	320,552	40.5	406,935	30.1	18,056	8.1	50,776	12.4
Inflammation	113,343	0.3	8,408	0.6	267	0.5	48,000	0.6	5,059	0.4	9,140	0.8	8,590	0.5	3,575	0.6	5,899	0.7	7,702	0.6	1,011	0.5	3,322	0.8
Coronary Artery Disease (CAD)	2,881,850	6.9	203,555	15.7	7,179	12.8	1,671,075	21.7	49,172	3.8	361,929	30.3	262,278	16.2	125,540	21.6	277,537	35.0	195,782	14.5	10,650	4.8	71,893	17.6
Heart Failure	1,406,425	3.4	121,090	9.3	5,635	10.1	978,596	12.7	20,985	1.6	257,584	21.6	118,205	7.3	65,057	11.2	254,403	32.1	101,889	7.5	4,899	2.2	37,463	9.2
Peripheral Artery Disease (PAD)	2,063,976	5.0	160,850	12.4	5,628	10.1	1,137,205	14.8	43,099	3.3	330,811	27.7	250,960	15.5	126,935	21.8	193,413	24.4	176,988	13.1	8,919	4.0	64,433	15.7
Fatty Liver Disease	970,623	2.3	68,385	5.3	1,850	3.3	393,675	5.1	33,602	2.6	89,109	7.5	131,157	8.1	41,889	7.2	59,655	7.5	128,013	9.5	14,849	6.7	16,849	4.1
Hyperthyroidism	305,426	0.7	45,466	3.5	49,564	88.7	116,273	1.5	14,447	1.1	20,349	1.7	22,007	1.4	8,047	1.4	13,055	1.6	19,521	1.4	2,720	1.2	9,419	2.3
Hypothyroidism	2,546,107	6.1	1,012,050	78.1	7,788	13.9	979,323	12.7	130,776	10.1	190,852	16.0	207,413	12.8	78,486	13.5	107,900	13.6	192,515	14.2	30,665	13.8	87,513	21.4
Peripheral Neuropathy	9,619	<0.1	865	0.1	16	<0.1	4,478	0.1	415	<0.1	921	0.1	766	<0.1	306	0.1	511	0.1	706	0.1	103	<0.1	400	0.1
Depression	4,585,163	11.0	292,387	22.5	8,739	15.6	1,471,046	19.1	273,894	21.2	290,357	24.3	335,329	20.7	110,519	19.0	158,105	20.0	361,466	26.7	77,043	34.7	92,089	22.5
Anxiety	6,643,706	16.0	360,447	27.8	12,610	22.6	1,898,736	24.7	387,047	29.9	318,986	26.7	387,251	23.9	120,075	20.6	174,863	22.1	430,316	31.8	94,051	42.3	109,852	26.9
Retinopathy	432,670	1.0	28,382	2.2	1,214	2.2	237,325	3.1	7,608	0.6	144,923	12.1	101,776	6.3	55,642	9.6	73,139	9.2	75,789	5.6	1,313	0.6	8,825	2.2
Gastroparesis	130,370	0.3	11,497	0.9	363	0.6	57,692	0.8	6,761	0.5	33,615	2.8	11,815	0.7	7,009	1.2	10,154	1.3	12,339	0.9	1,582	0.7	3,322	0.8
MEDICATIONS PRESCRIBED IN 2024																								
Antithyroid	55,888	0.1	2,473	0.2	55,888	100.0	30,033	0.4	2,567	0.2	4,950	0.4	5,192	0.3	2,108	0.4	3,154	0.4	3,538	0.3	372	0.2	2,007	0.5
Thyroid Replacement	1,296,629	3.1	1,296,629	100.0	2,473	4.4	659,776	8.6	92,034	7.1	130,498	10.9	150,244	9.3	55,497	9.5	71,215	9.0	116,704	8.6	20,936	9.4	56,530	13.8
Antihypertensive	7,688,502	18.5	659,776	50.9	30,033	53.7	7,688,502	100.0	280,239	21.6	828,420	69.4	1,065,330	65.8	431,218	74.1	620,367	78.3	725,312	53.6	74,796	33.7	208,484	51.0
Hormonal Therapies Containing Estrogens	1,294,890	3.1	92,034	7.1	2,567	4.6	280,239	3.6	1,294,890	100.0	28,103	2.4	61,420	3.8	12,737	2.2	16,315	2.1	73,236	5.4	21,368	9.6	27,283	6.7
Insulin	1,193,124	2.9	130,498	10.1	4,950	8.9	828,420	10.8	28,103	2.2	1,193,124	100.0	337,096	20.8	167,954	28.9	233,758	29.5	254,500	18.8	6,663	3.0	24,956	6.1
Metformin	1,619,736	3.9	150,244	11.6	5,192	9.3	1,065,330	13.9	61,420	4.7	337,096	28.3	1,619,736	100.0	344,705	59.3	346,740	43.8	426,509	31.5	25,830	11.6	32,042	7.8
Other Diabetes Medication	581,737	1.4	55,497	4.3	2,108	3.8	431,218	5.6	12,737	1.0	167,954	14.1	344,705	21.3	581,737	100.0	181,280	22.9	145,637	10.8	2,652	1.2	14,328	3.5
SGLT-2 Inhibitors	792,239	1.9	71,215	5.5	3,154	5.6	620,367	8.1	16,315	1.3	233,758	19.6	346,740	21.4	181,280	31.2	792,239	100.0	217,544	16.1	4,326	1.9	17,234	4.2
GLP 1 Agonists Including Tirzepatide	1,352,309	3.2	116,704	9.0	3,538	6.3	725,312	9.4	73,236	5.7	254,500	21.3	426,509	26.3	145,637	25.0	217,544	27.5	1,352,309	100.0	58,897	26.5	18,105	4.4
Non-GLP-1 Anti-obesity Agent	222,160	0.5	20,936	1.6	372	0.7	74,796	1.0	21,368	1.7	6,663	0.6	25,830	1.6	2,652	0.5	4,326	0.5	58,897	4.4	222,160	100.0	2,461	0.6
Osteoporosis Medication	409,099	1.0	56,530	4.4	2,007	3.6	208,484	2.7	27,283	2.1	24,956	2.1	32,042	2.0	14,328	2.5	17,234	2.2	18,105	1.3	2,461	1.1	409,099	100.0

¹Total only includes 71 data-contributing partners in PCORnet.

Table 8. Overlap between metabolic and endocrine conditions and medications prescribed for patients with at least 1 ambulatory visit at a site participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.¹

	Total Patients with Ambulatory Visits		Type 2 Diabetes		Type 1 Diabetes		Prediabetes		Impaired Fasting Glucose		Gestational Diabetes		Thyroid Disorder		Parathyroid Disorder		Bone Density Structure Disorder		Osteoporosis	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Number of unique patients	41,619,147	100	4,233,764	10.2	312,005	0.7	2,248,513	5.4	562,360	1.4	119,333	0.3	2,768,310	6.7	411,044	1.0	1,360,394	3.3	1,301,988	3.1
METABOLIC and ENDOCRINE CONDITIONS																				
Bone Density Structure Disorder	1,360,394	3.3	280,601	6.6	13,838	4.4	206,730	9.2	68,587	12.2	269	0.2	314,854	11.4	75,668	18.4	1,360,394	100.0	377,798	29.0
Osteoporosis	1,301,988	3.1	261,794	6.2	14,856	4.8	176,881	7.9	57,245	10.2	171	0.1	325,260	11.7	91,949	22.4	377,798	27.8	1,301,988	100.0
Thyroid Disorder	2,768,310	6.7	675,508	16.0	55,447	17.8	360,245	16.0	106,911	19.0	12,638	10.6	2,768,310	100.0	105,729	25.7	314,854	23.1	325,260	25.0
Parathyroid Disorder	411,044	1.0	168,439	4.0	13,448	4.3	50,884	2.3	13,862	2.5	330	0.3	105,729	3.8	411,044	100.0	75,668	5.6	91,949	7.1
Impaired Fasting Glucose	562,360	1.4	69,046	1.6	961	0.3	116,181	5.2	562,360	100.0	1,888	1.6	106,911	3.9	13,862	3.4	68,587	5.0	57,245	4.4
Prediabetes	2,248,513	5.4	387,435	9.2	4,312	1.4	2,248,513	100.0	116,181	20.7	12,159	10.2	360,245	13.0	50,884	12.4	206,730	15.2	176,881	13.6
Diabetes - Type 1	312,005	0.7	150,106	3.5	312,005	100.0	4,312	0.2	961	0.2	1,521	1.3	55,447	2.0	13,448	3.3	13,838	1.0	14,856	1.1
Diabetes - Type 2	4,233,764	10.2	4,233,764	100.0	150,106	48.1	387,435	17.2	69,046	12.3	13,937	11.7	675,508	24.4	168,439	41.0	280,601	20.6	261,794	20.1
Gestational Diabetes	119,333	0.3	13,937	0.3	1,521	0.5	12,159	0.5	1,888	0.3	119,333	100.0	12,638	0.5	330	0.1	269	<0.1	171	<0.1
Polycystic Ovary Syndrome (PCOS)	307,682	0.7	37,448	0.9	3,068	1.0	45,482	2.0	6,562	1.2	8,033	6.7	42,635	1.5	2,331	0.6	2,390	0.2	1,454	0.1
Steatohepatitis (MASH)	137,071	0.3	67,864	1.6	2,540	0.8	19,707	0.9	4,908	0.9	358	0.3	28,196	1.0	5,180	1.3	13,278	1.0	11,589	0.9
Hypertension	9,974,076	24.0	3,239,046	76.5	133,409	42.8	1,310,205	58.3	349,631	62.2	16,015	13.4	1,509,855	54.5	324,283	78.9	775,582	57.0	770,395	59.2
Pure Hypertriglyceridemia	478,141	1.1	150,315	3.6	7,038	2.3	96,700	4.3	22,367	4.0	1,380	1.2	62,928	2.3	10,279	2.5	26,013	1.9	20,533	1.6
HDL Deficiency	73,629	0.2	14,328	0.3	753	0.2	16,612	0.7	4,007	0.7	182	0.2	7,430	0.3	1,085	0.3	2,623	0.2	1,975	0.2
Hypercholesteremia	9,587,923	23.0	2,981,598	70.4	142,636	45.7	1,510,424	67.2	426,669	75.9	10,555	8.8	1,591,363	57.5	274,587	66.8	865,646	63.6	833,461	64.0
Metabolic Syndrome	71,013	0.2	22,478	0.5	1,122	0.4	20,864	0.9	5,107	0.9	324	0.3	13,515	0.5	2,253	0.5	5,220	0.4	3,570	0.3
Overweight - Adult	1,236,802	3.0	278,577	6.6	16,416	5.3	152,744	6.8	38,936	6.9	3,604	3.0	174,740	6.3	34,600	8.4	98,893	7.3	81,899	6.3
Obese Class 1 - Adult	2,200,939	5.3	613,771	14.5	27,228	8.7	356,188	15.8	82,191	14.6	10,962	9.2	325,738	11.8	64,221	15.6	150,264	11.0	109,956	8.4
Obese Class 2 - Adult	1,565,540	3.8	515,205	12.2	19,250	6.2	280,748	12.5	60,029	10.7	10,653	8.9	244,453	8.8	49,503	12.0	91,240	6.7	64,791	5.0
Obese Class 3 - Adult	1,537,951	3.7	529,887	12.5	15,858	5.1	294,638	13.1	56,431	10.0	13,600	11.4	240,079	8.7	43,056	10.5	61,492	4.5	45,538	3.5
Overweight - Child	435,593	1.0	1,853	<0.1	2,701	0.9	6,765	0.3	441	0.1	37	<0.1	3,456	0.1	355	0.1	1,410	0.1	214	<0.1
Obese - Child	508,602	1.2	11,763	0.3	6,063	1.9	33,878	1.5	1,827	0.3	132	0.1	9,586	0.3	799	0.2	3,126	0.2	489	<0.1
Severely Obese - Child	10,975	<0.1	650	<0.1	195	0.1	1,858	0.1	72	<0.1	-	<0.1	377	<0.1	56	<0.1	122	<0.1	35	<0.1
ADDITIONAL CONDITIONS																				
Cardiovascular Disease	10,885,856	26.2	3,356,224	79.3	141,335	45.3	1,369,623	60.9	365,531	65.0	17,324	14.5	1,607,797	58.1	333,507	81.1	834,940	61.4	833,595	64.0
Chronic Kidney Disease	2,594,518	6.2	1,176,878	27.8	72,562	23.3	248,759	11.1	74,468	13.2	2,550	2.1	464,728	16.8	257,600	62.7	229,137	16.8	243,526	18.7
Sleep Apnea	2,962,356	7.1	869,066	20.5	33,463	10.7	411,384	18.3	109,461	19.5	3,995	3.3	447,039	16.1	94,086	22.9	197,563	14.5	167,947	12.9
Breast Cancer	567,253	1.4	99,879	2.4	3,648	1.2	57,455	2.6	16,145	2.9	325	0.3	98,590	3.6	15,509	3.8	140,795	10.3	107,130	8.2
Dyslipidemia	9,869,158	23.7	3,026,428	71.5	145,419	46.6	1,556,471	69.2	436,865	77.7	11,895	10.0	1,618,190	58.5	277,232	67.4	874,849	64.3	840,581	64.6
Hyper- or Hypo- Glycemia	2,454,439	5.9	1,547,097	36.5	202,580	64.9	219,546	9.8	47,133	8.4	8,430	7.1	421,623	15.2	105,353	25.6	190,335	14.0	181,476	13.9
Inflammation	113,343	0.3	29,105	0.7	1,487	0.5	13,813	0.6	3,523	0.6	218	0.2	16,937	0.6	3,824	0.9	10,715	0.8	11,101	0.9
Coronary Artery Disease (CAD)	2,881,850	6.9	1,070,537	25.3	46,586	14.9	332,933	14.8	97,970	17.4	804	0.7	488,538	17.6	125,790	30.6	249,926	18.4	267,409	20.5
Heart Failure	1,406,425	3.4	620,587	14.7	27,003	8.7	144,399	6.4	36,048	6.4	697	0.6	285,566	10.3	101,569	24.7	119,477	8.8	145,121	11.1
Peripheral Artery Disease (PAD)	2,063,976	5.0	954,769	22.6	50,953	16.3	213,658	9.5	58,265	10.4	1,040	0.9	372,754	13.5	119,683	29.1	227,896	16.8	235,137	18.1

Fatty Liver Disease	970,623	2.3	328,504	7.8	12,429	4.0	169,037	7.5	39,429	7.0	3,915	3.3	154,306	5.6	24,809	6.0	79,414	5.8	60,690	4.7
Hyperthyroidism	305,426	0.7	63,223	1.5	6,002	1.9	40,181	1.8	9,121	1.6	1,936	1.6	305,426	11.0	15,843	3.9	29,830	2.2	31,702	2.4
Hypothyroidism	2,546,107	6.1	634,370	15.0	51,646	16.6	332,463	14.8	101,071	18.0	11,423	9.6	2,546,107	92.0	96,225	23.4	296,847	21.8	306,109	23.5
Peripheral Neuropathy	9,619	<0.1	2,747	0.1	198	0.1	1,223	0.1	354	0.1	-	<0.1	1,845	0.1	441	0.1	1,186	0.1	1,200	0.1
Depression	4,585,163	11.0	872,285	20.6	60,613	19.4	486,190	21.6	120,421	21.4	25,712	21.5	673,259	24.3	101,182	24.6	308,744	22.7	308,421	23.7
Anxiety	6,643,706	16.0	969,916	22.9	71,001	22.8	631,683	28.1	165,250	29.4	32,676	27.4	825,871	29.8	113,900	27.7	378,320	27.8	368,835	28.3
Retinopathy	432,670	1.0	335,631	7.9	56,222	18.0	16,537	0.7	2,807	0.5	478	0.4	62,416	2.3	36,458	8.9	34,732	2.6	31,225	2.4
Gastroparesis	130,370	0.3	60,911	1.4	15,557	5.0	7,987	0.4	2,054	0.4	239	0.2	27,088	1.0	9,310	2.3	12,701	0.9	14,079	1.1
MEDICATIONS PRESCRIBED IN 2024																				
Antithyroid	55,888	0.1	11,061	0.3	1,112	0.4	6,811	0.3	1,326	0.2	255	0.2	50,110	1.8	2,143	0.5	4,636	0.3	5,111	0.4
Thyroid Replacement	1,296,629	3.1	291,313	6.9	26,640	8.5	173,808	7.7	48,478	8.6	5,152	4.3	1,025,137	37.0	52,386	12.7	148,325	10.9	146,562	11.3
Antihypertensive	7,688,502	18.5	2,206,148	52.1	97,456	31.2	976,770	43.4	265,741	47.3	18,432	15.4	1,057,643	38.2	233,763	56.9	569,889	41.9	556,514	42.7
Hormonal Therapies Containing Estrogens	1,294,890	3.1	85,042	2.0	8,156	2.6	88,984	4.0	21,504	3.8	7,041	5.9	140,600	5.1	14,034	3.4	87,581	6.4	72,072	5.5
Insulin	1,193,124	2.9	890,540	21.0	191,337	61.3	47,473	2.1	8,902	1.6	16,350	13.7	203,084	7.3	67,332	16.4	73,330	5.4	77,501	6.0
Metformin	1,619,736	3.9	1,256,903	29.7	25,778	8.3	242,012	10.8	37,386	6.6	12,692	10.6	222,907	8.1	25,571	6.2	96,818	7.1	77,293	5.9
Other Diabetes Medication	581,737	1.4	535,455	12.6	8,738	2.8	15,884	0.7	3,558	0.6	760	0.6	84,108	3.0	19,890	4.8	38,012	2.8	35,282	2.7
SGLT-2 Inhibitors	792,239	1.9	606,868	14.3	14,567	4.7	54,202	2.4	10,862	1.9	691	0.6	116,473	4.2	33,339	8.1	50,910	3.7	47,076	3.6
GLP 1 Agonists Including Tirzepatide	1,352,309	3.2	764,097	18.0	26,487	8.5	205,076	9.1	42,336	7.5	5,212	4.4	205,746	7.4	34,685	8.4	69,935	5.1	49,911	3.8
Non-GLP-1 Anti-obesity Agent	222,160	0.5	22,145	0.5	1,612	0.5	37,272	1.7	9,375	1.7	1,328	1.1	32,407	1.2	3,143	0.8	9,011	0.7	6,623	0.5
Osteoporosis Medication	409,099	1.0	74,093	1.8	4,001	1.3	55,708	2.5	17,877	3.2	31	<0.1	93,325	3.4	27,078	6.6	137,369	10.1	299,197	23.0

¹Total only includes 71 data-contributing partners in PCORnet.

Table 9. Overlap between metabolic and endocrine conditions and medications prescribed for patients with at least 1 ambulatory visit at a site participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.¹

	Total Patients with Ambulatory Visits		Hypertension		Hypercholesterolemia		Pure Hypertriglyceridemia		Polycystic Ovary Syndrome (PCOS)		Steatohepatitis (MASH)		HDL Deficiency		Metabolic Syndrome as designated by ICD-10 Code	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Number of unique patients	41,619,147	100	9,974,076	24.0	9,587,923	23.0	478,141	1.1	307,682	0.7	137,071	0.3	73,629	0.2	71,013	0.2
METABOLIC and ENDOCRINE CONDITIONS																
Bone Density Structure Disorder	1,360,394	3.3	775,582	7.8	865,646	9.0	26,013	5.4	2,390	0.8	13,278	9.7	2,623	3.6	5,220	7.4
Osteoporosis	1,301,988	3.1	770,395	7.7	833,461	8.7	20,533	4.3	1,454	0.5	11,589	8.5	1,975	2.7	3,570	5.0
Thyroid Disorder	2,768,310	6.7	1,509,855	15.1	1,591,363	16.6	62,928	13.2	42,635	13.9	28,196	20.6	7,430	10.1	13,515	19.0
Parathyroid Disorder	411,044	1.0	324,283	3.3	274,587	2.9	10,279	2.1	2,331	0.8	5,180	3.8	1,085	1.5	2,253	3.2
Impaired Fasting Glucose	562,360	1.4	349,631	3.5	426,669	4.5	22,367	4.7	6,562	2.1	4,908	3.6	4,007	5.4	5,107	7.2
Prediabetes	2,248,513	5.4	1,310,205	13.1	1,510,424	15.8	96,700	20.2	45,482	14.8	19,707	14.4	16,612	22.6	20,864	29.4
Diabetes - Type 1	312,005	0.7	133,409	1.3	142,636	1.5	7,038	1.5	3,068	1.0	2,540	1.9	753	1.0	1,122	1.6
Diabetes - Type 2	4,233,764	10.2	3,239,046	32.5	2,981,598	31.1	150,315	31.4	37,448	12.2	67,864	49.5	14,328	19.5	22,478	31.7
Gestational Diabetes	119,333	0.3	16,015	0.2	10,555	0.1	1,380	0.3	8,033	2.6	358	0.3	182	0.2	324	0.5
Polycystic Ovary Syndrome (PCOS)	307,682	0.7	57,304	0.6	65,561	0.7	8,896	1.9	307,682	100.0	3,292	2.4	1,758	2.4	4,921	6.9
Steatohepatitis (MASH)	137,071	0.3	88,879	0.9	84,055	0.9	8,100	1.7	3,292	1.1	137,071	100.0	970	1.3	3,381	4.8
Hypertension	9,974,076	24.0	9,974,076	100.0	6,456,845	67.3	250,063	52.3	57,304	18.6	88,879	64.8	29,728	40.4	43,420	61.1
Pure Hypertriglyceridemia	478,141	1.1	250,063	2.5	270,551	2.8	478,141	100.0	8,896	2.9	8,100	5.9	17,074	23.2	5,514	7.8
HDL Deficiency	73,629	0.2	29,728	0.3	35,166	0.4	17,074	3.6	1,758	0.6	970	0.7	73,629	100.0	1,221	1.7
Hypercholesterolemia	9,587,923	23.0	6,456,845	64.7	9,587,923	100.0	270,551	56.6	65,561	21.3	84,055	61.3	35,166	47.8	47,498	66.9
Metabolic Syndrome	71,013	0.2	43,420	0.4	47,498	0.5	5,514	1.2	4,921	1.6	3,381	2.5	1,221	1.7	71,013	100.0
Overweight - Adult	1,236,802	3.0	619,993	6.2	652,021	6.8	35,629	7.5	11,934	3.9	12,575	9.2	5,011	6.8	5,043	7.1
Obese Class 1 - Adult	2,200,939	5.3	1,261,848	12.7	1,247,822	13.0	75,287	15.7	38,516	12.5	29,295	21.4	10,297	14.0	17,352	24.4
Obese Class 2 - Adult	1,565,540	3.8	963,418	9.7	871,324	9.1	53,460	11.2	42,801	13.9	25,897	18.9	8,069	11.0	17,363	24.5
Obese Class 3 - Adult	1,537,951	3.7	949,873	9.5	743,001	7.7	44,813	9.4	68,048	22.1	25,684	18.7	8,607	11.7	20,425	28.8
Overweight - Child	435,593	1.0	5,260	0.1	17,875	0.2	9,320	1.9	1,852	0.6	299	0.2	2,510	3.4	297	0.4
Obese - Child	508,602	1.2	23,981	0.2	47,936	0.5	25,842	5.4	9,761	3.2	2,840	2.1	8,288	11.3	2,381	3.4
Severely Obese - Child	10,975	<0.1	1,282	<0.1	2,191	<0.1	1,215	0.3	393	0.1	152	0.1	511	0.7	201	0.3
ADDITIONAL CONDITIONS																
Cardiovascular Disease	10,885,856	26.2	9,974,076	100.0	6,738,449	70.3	260,524	54.5	61,830	20.1	93,640	68.3	31,371	42.6	44,831	63.1
Chronic Kidney Disease	2,594,518	6.2	2,048,254	20.5	1,705,338	17.8	68,989	14.4	9,671	3.1	33,947	24.8	7,367	10.0	10,700	15.1
Sleep Apnea	2,962,356	7.1	1,791,065	18.0	1,629,733	17.0	85,605	17.9	35,003	11.4	42,268	30.8	13,281	18.0	23,361	32.9
Breast Cancer	567,253	1.4	254,389	2.6	247,388	2.6	7,192	1.5	1,946	0.6	4,185	3.1	684	0.9	1,659	2.3
Dyslipidemia	9,869,158	23.7	6,552,954	65.7	9,587,923	100.0	478,141	100.0	71,707	23.3	86,573	63.2	73,629	100.0	49,593	69.8
Hyper- or Hypo- Glycemia	2,454,439	5.9	1,685,468	16.9	1,674,355	17.5	99,162	20.7	25,673	8.3	39,087	28.5	10,468	14.2	14,686	20.7
Inflammation	113,343	0.3	57,620	0.6	52,507	0.5	2,108	0.4	729	0.2	1,146	0.8	276	0.4	425	0.6
Coronary Artery Disease (CAD)	2,881,850	6.9	2,356,774	23.6	2,287,635	23.9	65,618	13.7	4,684	1.5	30,500	22.3	8,316	11.3	12,964	18.3
Heart Failure	1,406,425	3.4	1,217,671	12.2	1,015,300	10.6	29,346	6.1	2,850	0.9	17,316	12.6	3,197	4.3	6,278	8.8
Peripheral Artery Disease (PAD)	2,063,976	5.0	1,613,827	16.2	1,455,696	15.2	51,232	10.7	6,188	2.0	27,421	20.0	5,674	7.7	8,942	12.6
Fatty Liver Disease	970,623	2.3	561,924	5.6	559,506	5.8	55,558	11.6	22,867	7.4	64,203	46.8	6,912	9.4	13,084	18.4

Hyperthyroidism	305,426	0.7	145,142	1.5	135,950	1.4	5,453	1.1	4,198	1.4	2,081	1.5	832	1.1	1,208	1.7
Hypothyroidism	2,546,107	6.1	1,414,236	14.2	1,503,454	15.7	59,431	12.4	39,798	12.9	27,151	19.8	6,833	9.3	12,827	18.1
Peripheral Neuropathy	9,619	<0.1	5,951	0.1	5,398	0.1	256	0.1	88	<0.1	136	0.1	34	<0.1	27	<0.1
Depression	4,585,163	11.0	1,935,953	19.4	1,889,442	19.7	107,880	22.6	88,016	28.6	38,671	28.2	13,812	18.8	19,262	27.1
Anxiety	6,643,706	16.0	2,436,796	24.4	2,399,967	25.0	143,624	30.0	119,125	38.7	45,202	33.0	19,915	27.0	24,773	34.9
Retinopathy	432,670	1.0	308,099	3.1	279,602	2.9	13,910	2.9	1,753	0.6	5,889	4.3	1,251	1.7	1,761	2.5
Gastroparesis	130,370	0.3	77,023	0.8	67,761	0.7	4,152	0.9	2,769	0.9	4,013	2.9	306	0.4	759	1.1
MEDICATIONS PRESCRIBED IN 2024																
Antithyroid	55,888	0.1	24,386	0.2	20,622	0.2	733	0.2	517	0.2	245	0.2	143	0.2	143	0.2
Thyroid Replacement	1,296,629	3.1	644,049	6.5	690,934	7.2	29,593	6.2	18,452	6.0	13,005	9.5	3,430	4.7	6,241	8.8
Antihypertensive	7,688,502	18.5	5,893,689	59.1	4,415,021	46.0	187,603	39.2	58,579	19.0	65,810	48.0	22,595	30.7	30,680	43.2
Hormonal Therapies Containing Estrogens	1,294,890	3.1	235,849	2.4	289,692	3.0	16,484	3.4	50,210	16.3	4,583	3.3	2,008	2.7	3,655	5.1
Insulin	1,193,124	2.9	852,561	8.5	781,301	8.1	42,287	8.8	9,517	3.1	22,888	16.7	3,214	4.4	6,279	8.8
Metformin	1,619,736	3.9	1,085,383	10.9	1,091,147	11.4	74,872	15.7	57,956	18.8	21,438	15.6	8,320	11.3	15,175	21.4
Other Diabetes Medication	581,737	1.4	445,404	4.5	436,350	4.6	26,124	5.5	2,521	0.8	8,087	5.9	2,316	3.1	2,142	3.0
SGLT-2 Inhibitors	792,239	1.9	620,870	6.2	587,712	6.1	33,931	7.1	4,707	1.5	11,805	8.6	2,983	4.1	4,712	6.6
GLP 1 Agonists Including Tirzepatide	1,352,309	3.2	817,461	8.2	811,882	8.5	55,659	11.6	44,834	14.6	24,190	17.6	7,276	9.9	20,292	28.6
Non-GLP-1 Anti-obesity Agent	222,160	0.5	76,355	0.8	79,930	0.8	5,727	1.2	10,695	3.5	2,138	1.6	1,230	1.7	4,112	5.8
Osteoporosis Medication	409,099	1.0	227,386	2.3	247,426	2.6	6,263	1.3	297	0.1	3,047	2.2	574	0.8	856	1.2

¹Total only includes 71 data-contributing partners in PCORnet.

Table 10. Overlap between with diagnosis codes for obesity and overweight and medications prescribed for patients with at least 1 ambulatory visit at a site participating in PCORnet between January 1, 2024 – December 31, 2024, and a diagnosis code related to metabolic or endocrine conditions between January 1, 2020 – December 31, 2024.¹

	Total Patients with Ambulatory Visits		Adults								Pediatrics					
			Overweight Adults		Obese Class 1 Adults		Obese Class 2 Adults		Obese Class 3 Adults		Overweight		Obesity		Severe Obesity	
			N	%	N	%	N	%	N	%	N	%	N	%	N	%
Number of unique patients	41,619,147	100	1,226,632	2.9	2,183,634	5.2	1,552,207	3.7	1,521,251	3.7	431,363	1.0	498,574	1.2	10,472	<0.1
METABOLIC and ENDOCRINE CONDITIONS																
Bone Density Structure Disorder	1,360,394	3.3	98,875	8.1	150,198	6.9	91,186	5.9	61,426	4.0	1,364	0.3	2,938	0.6	93	0.9
Osteoporosis	1,301,988	3.1	81,892	6.7	109,937	5.0	64,777	4.2	45,523	3.0	185	<0.1	366	0.1	-	<0.1
Thyroid Disorder	2,768,310	6.7	174,556	14.2	325,178	14.9	243,967	15.7	239,355	15.7	3,216	0.7	8,786	1.8	307	2.9
Parathyroid Disorder	411,044	1.0	34,586	2.8	64,183	2.9	49,460	3.2	43,006	2.8	318	0.1	720	0.1	42	0.4
Impaired Fasting Glucose	562,360	1.4	38,900	3.2	82,069	3.8	59,921	3.9	56,287	3.7	412	0.1	1,702	0.3	53	0.5
Prediabetes	2,248,513	5.4	152,397	12.4	354,834	16.2	279,186	18.0	291,836	19.2	6,551	1.5	32,682	6.6	1,744	16.7
Diabetes - Type 1	312,005	0.7	16,309	1.3	26,933	1.2	19,029	1.2	15,632	1.0	2,583	0.6	5,804	1.2	189	1.8
Diabetes - Type 2	4,233,764	10.2	278,467	22.7	613,190	28.1	514,517	33.1	528,605	34.7	1,618	0.4	10,427	2.1	479	4.6
Gestational Diabetes	119,333	0.3	3,596	0.3	10,931	0.5	10,620	0.7	13,565	0.9	20	<0.1	68	<0.1	-	<0.1
Polycystic Ovary Syndrome (PCOS)	307,682	0.7	11,720	1.0	37,696	1.7	41,832	2.7	66,428	4.4	1,662	0.4	8,814	1.8	378	3.6
Steatohepatitis (MASH)	137,071	0.3	12,558	1.0	29,166	1.3	25,724	1.7	25,443	1.7	279	0.1	2,672	0.5	143	1.4
Hypertension	9,974,076	24.0	619,681	50.5	1,260,760	57.7	962,203	62.0	947,525	62.3	4,867	1.1	21,738	4.4	966	9.2
Pure Hypertriglyceridemia	478,141	1.1	35,332	2.9	74,304	3.4	52,497	3.4	43,598	2.9	9,185	2.1	25,325	5.1	1,200	11.5
HDL Deficiency	73,629	0.2	4,912	0.4	9,935	0.5	7,603	0.5	7,932	0.5	2,451	0.6	8,104	1.6	511	4.9
Hypercholesteremia	9,587,923	23.0	651,057	53.1	1,245,314	57.0	868,911	56.0	739,975	48.6	17,306	4.0	45,581	9.1	1,903	18.2
Metabolic Syndrome	71,013	0.2	5,027	0.4	17,233	0.8	17,194	1.1	20,036	1.3	277	0.1	2,240	0.4	182	1.7
Overweight - Adult	1,236,802	3.0	1,226,632	100.0	282,876	13.0	44,211	2.8	16,542	1.1	2,827	0.7	1,484	0.3	-	<0.1
Obese Class 1 - Adult	2,200,939	5.3	282,876	23.1	2,183,634	100.0	407,399	26.2	86,651	5.7	1,736	0.4	6,471	1.3	133	1.3
Obese Class 2 - Adult	1,565,540	3.8	44,211	3.6	407,399	18.7	1,552,207	100.0	325,454	21.4	474	0.1	6,232	1.2	435	4.2
Obese Class 3 - Adult	1,537,951	3.7	16,542	1.3	86,651	4.0	325,454	21.0	1,521,251	100.0	431	0.1	8,648	1.7	783	7.5
Overweight - Child	435,593	1.0	1,013	0.1	872	<0.1	333	<0.1	333	<0.1	431,363	100.0	64,300	12.9	285	2.7
Obese - Child	508,602	1.2	698	0.1	2,468	0.1	2,723	0.2	3,798	0.2	64,300	14.9	498,574	100.0	6,503	62.1
Severely Obese - Child	10,975	<0.1	19	<0.1	113	<0.1	186	<0.1	179	<0.1	285	0.1	6,503	1.3	10,472	100.0
ADDITIONAL CONDITIONS																
Cardiovascular Disease	10,885,856	26.2	656,509	53.5	1,314,666	60.2	996,886	64.2	981,166	64.5	6,414	1.5	24,341	4.9	1,029	9.8
Chronic Kidney Disease	2,594,518	6.2	200,142	16.3	362,876	16.6	266,863	17.2	232,948	15.3	2,595	0.6	5,215	1.0	152	1.5
Sleep Apnea	2,962,356	7.1	157,930	12.9	452,864	20.7	440,158	28.4	534,206	35.1	13,268	3.1	46,452	9.3	2,065	19.7
Breast Cancer	567,253	1.4	30,409	2.5	55,658	2.5	38,587	2.5	30,742	2.0	-	<0.1	-	<0.1	0	0.0
Dyslipidemia	9,869,158	23.7	665,069	54.2	1,275,156	58.4	891,231	57.4	762,014	50.1	26,227	6.1	66,370	13.3	2,764	26.4
Hyper- or Hypo- Glycemia	2,454,439	5.9	192,362	15.7	376,793	17.3	299,564	19.3	287,004	18.9	5,114	1.2	15,924	3.2	575	5.5
Inflammation	113,343	0.3	6,279	0.5	12,922	0.6	10,620	0.7	13,617	0.9	217	0.1	311	0.1	-	<0.1
Coronary Artery Disease (CAD)	2,881,850	6.9	213,772	17.4	389,960	17.9	266,513	17.2	204,287	13.4	269	0.1	517	0.1	13	0.1
Heart Failure	1,406,425	3.4	113,408	9.2	210,660	9.6	172,301	11.1	180,298	11.9	301	0.1	711	0.1	19	0.2
Peripheral Artery Disease (PAD)	2,063,976	5.0	172,702	14.1	303,826	13.9	220,848	14.2	187,863	12.3	1,260	0.3	2,181	0.4	71	0.7
Fatty Liver Disease	970,623	2.3	72,928	5.9	180,360	8.3	151,155	9.7	150,062	9.9	1,739	0.4	14,612	2.9	842	8.0

Hyperthyroidism	305,426	0.7	19,549	1.6	34,075	1.6	24,434	1.6	21,212	1.4	483	0.1	889	0.2	41	0.4
Hypothyroidism	2,546,107	6.1	162,164	13.2	303,224	13.9	228,486	14.7	226,013	14.9	2,815	0.7	8,091	1.6	277	2.6
Peripheral Neuropathy	9,619	<0.1	932	0.1	1,369	0.1	972	0.1	825	0.1	-	<0.1	14	<0.1	0	0.0
Depression	4,585,163	11.0	287,565	23.4	542,963	24.9	432,455	27.9	456,804	30.0	30,706	7.1	50,570	10.1	1,233	11.8
Anxiety	6,643,706	16.0	371,193	30.3	685,334	31.4	521,249	33.6	533,593	35.1	63,974	14.8	91,611	18.4	2,252	21.5
Retinopathy	432,670	1.0	30,832	2.5	61,555	2.8	47,866	3.1	42,147	2.8	603	0.1	588	0.1	13	0.1
Gastroparesis	130,370	0.3	12,896	1.1	20,582	0.9	15,926	1.0	14,368	0.9	474	0.1	696	0.1	15	0.1
MEDICATIONS PRESCRIBED IN 2024																
Antithyroid	55,888	0.1	3,177	0.3	5,195	0.2	3,601	0.2	3,222	0.2	117	<0.1	222	<0.1	-	<0.1
Thyroid Replacement	1,296,629	3.1	81,517	6.6	148,312	6.8	110,059	7.1	107,813	7.1	1,662	0.4	4,775	1.0	172	1.6
Antihypertensive	7,688,502	18.5	455,811	37.2	920,202	42.1	694,169	44.7	672,407	44.2	4,828	1.1	12,947	2.6	481	4.6
Hormonal Therapies Containing Estrogens	1,294,890	3.1	49,008	4.0	86,234	3.9	59,200	3.8	54,112	3.6	7,435	1.7	11,513	2.3	328	3.1
Insulin	1,193,124	2.9	92,101	7.5	180,600	8.3	143,908	9.3	140,446	9.2	2,148	0.5	5,583	1.1	188	1.8
Metformin	1,619,736	3.9	102,855	8.4	244,345	11.2	204,100	13.1	214,201	14.1	1,353	0.3	13,161	2.6	1,034	9.9
Other Diabetes Medication	581,737	1.4	42,243	3.4	82,478	3.8	62,579	4.0	56,233	3.7	52	<0.1	195	<0.1	-	<0.1
SGLT-2 Inhibitors	792,239	1.9	53,973	4.4	120,783	5.5	96,823	6.2	91,083	6.0	93	<0.1	579	0.1	44	0.4
GLP 1 Agonists Including Tirzepatide	1,352,309	3.2	73,402	6.0	279,716	12.8	274,427	17.7	329,405	21.7	558	0.1	9,229	1.9	966	9.2
Non-GLP-1 Anti-obesity Agent	222,160	0.5	16,827	1.4	53,676	2.5	47,624	3.1	53,990	3.5	283	0.1	2,594	0.5	290	2.8
Osteoporosis Medication	409,099	1.0	25,486	2.1	32,096	1.5	17,957	1.2	12,025	0.8	38	<0.1	105	<0.1	-	<0.1

¹Total only includes 71 data-contributing partners in PCORnet.